Skip to main content
SpringerLink
Log in

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide

Fixed-Dose Combination in Hypertension

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The antihypertensive agents olmesartan medoxomil, amlodipine and hydrochlorothiazide (HCTZ) are now available as a fixed-dose combination tablet (olmesartan medoxomil/amlodipine/HCTZ).

In a 12-week, randomized, double-blind, multi-centre trial (TRINITY) in adults with moderate to severe hypertension, olmesartan medoxomil + amlodipine + HCTZ triple combination therapy produced significantly greater least squares mean reductions from baseline in seated diastolic blood pressure (BP) [primary endpoint] and seated systolic BP than olmesartan medoxomil/amlodipine, olmesartan medoxomil/HCTZ or amlodipine + HCTZ.

Furthermore, significantly more patients achieved BP goals and targets with the triple combination regimen than with any of the dual combination regimens at week 12, with olmesartan medoxomil + amlodipine + HCTZ also demonstrating benefit over the dual regimens in terms of ambulatory BP control.

According to subgroup analyses of the TRINITY trial, olmesartan medoxomil + amlodipine + HCTZ was more effective in reducing BP and achieving BP goals than each of the dual therapies, irrespective of hypertension severity, age, sex, race or diabetes mellitus status.

Data from a number of smaller clinical studies indicated that olmesartan medoxomil + amlodipine+ HCTZ triple combination therapy provides antihypertensive efficacy in patients whose BP is not adequately controlled with olmesartan medoxomil + amlodipine.

Olmesartan medoxomil + amlodipine + HCTZ was generally well tolerated in the TRINITY study, with adverse events usually being mild or moderate in severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Whitworth JA. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21(11): 1983–92

    Article  PubMed  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 — complete version. Hypertension 2003 Dec; 42(6): 1206–52

    Article  CAS  PubMed  Google Scholar 

  3. Safar ME, Struijker-Boudier HAJ. New goals in hypertension management: target-organ protection beyond blood pressure lowering [in French]. Drugs 2003; 63 (Special Issue 1): 45–7

    Article  PubMed  Google Scholar 

  4. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27(11): 2121–58

    Article  CAS  PubMed  Google Scholar 

  5. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 Jun; 28(12): 1462–536

    PubMed  Google Scholar 

  6. Wetzels GEC, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004 Oct; 22(10): 1849–55

    Article  CAS  PubMed  Google Scholar 

  7. Daiichi Sankyo Inc. Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200175s000lbl.pdf [Accessed 2010 Aug 19]

  8. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68(9): 1239–72

    Article  CAS  PubMed  Google Scholar 

  9. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov; 50 (5): 896]. Drugs 1995 Sep; 50(3): 560–86

    Article  CAS  PubMed  Google Scholar 

  10. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992 Jan; 22(1): 22–31

    Article  CAS  PubMed  Google Scholar 

  11. Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs 2006; 66(14): 1881–901

    Article  CAS  PubMed  Google Scholar 

  12. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag 2009; 5(1): 301–14

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Armas Padilla MC, Armas-Hernández MJ, Hernández RH, et al. Update of diuretics in the treatment of hypertension. Am J Ther 2007 Mar–Apr; 14(2): 154–60

    Article  Google Scholar 

  14. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001 May; 41(5): 515–27

    Article  CAS  PubMed  Google Scholar 

  15. Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 1988 Nov; 28(11): 990–4

    Article  CAS  PubMed  Google Scholar 

  16. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12(4): 297–303

    Article  CAS  PubMed  Google Scholar 

  17. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010 Jul; 32(7): 1252–69

    Article  CAS  PubMed  Google Scholar 

  18. Izzo J, Melino M, Fernandez V, et al. Twenty-four hour efficacy and safety of full-dose, triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide [abstract no. PO-39]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A34–5

    Article  Google Scholar 

  19. Oparil S, Littlejohn T, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension and diabetes (the TRINITY study) [abstract no. 670-P]. 70th Annual Scientific Sessions of the American Diabetes Association; 2010 Jun 25–29; Orlando (FL)

  20. Chrysant SG, Melino M, Fernandez V, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+ amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension: analysis by age and gender [abstract no. PO-30]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A30–1

    Google Scholar 

  21. Littlejohn T, Toth P, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) — the TRINITY study: a subgroup analysis by race [abstract no. PO-50]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A39

    Google Scholar 

  22. Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009; 29(6): 381–91

    Article  CAS  PubMed  Google Scholar 

  23. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertension 2009 Sep; 11(9): 475–82

    Article  CAS  Google Scholar 

  24. Kereiakes DJ, Sachson RA, Qian C, et al. Efficacy and onset of antihypertensive effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension and type 2 diabetes [abstract no. PO-233]. J Clin Hypertension 2010 Apr; 12 Suppl. 1: A111–2

    Google Scholar 

  25. FirstWordSM. Daiichi Sankyo announces first European approval for Sevikar HCT [media release]. 2010 Dec 20

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: H.R. Brunner, University of Lausanne, Lausanne, Switzerland; M. Volpe, Division of Cardiology, Faculty of Medicine, Sapienza University of Rome, Sant’Andrea Hospital, Rome, Italy.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered the opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deeks, E.D. Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide. Drugs 71, 209–220 (2011). https://doi.org/10.2165/11206770-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11206770-000000000-00000

Keywords

Search

Navigation